2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH FRED SAAD
Delaying Disease Progression in Early Nonmetastatic CRPC Treatment

VIEW ALL ASCO GU 2019 VIDEOS

Prostate Cancer Foundation 2018 Scientific Retreat

Prostate Cancer Foundation 2018 Scientific Retreat

INTERVIEW WITH ALAN BRYCE
Results from TRITON2: Treatment of mCRPC with Rucaparib

VIEW ALL PCF VIDEOS

European Society for Medical Oncology 2018 Congress

European Society for Medical Oncology 2018 Congress

PANEL DISCUSSION
Current Management of Bone Metastatic Castrate-Resistant Prostate Cancer

VIEW ALL ESMO VIDEOS

European Society for Medical Oncology 2018 Congress

 European Society for Medical Oncology 2018 Congress

INTERVIEW WITH ARJUN BALAR
Immunotherapy in Bladder Cancer

VIEW ALL ESMO VIDEOS


Notice: Trying to get property of non-object in /home/urotoday/public_html/templates/t3_bs3_blank/html/mod_media_media/carousel-featured.php on line 18
Featured Videos

#AUA14 - Longitudinal analysis of PSA doubling time following radical prostatectomy (RP) - Session Highlights

ORLANDO, FL USA (UroToday.com) - Recurrence rates and survival rates are associated with PSA doubling time in patients following radical prostatectomy. Adam Gordon and colleagues, in this observational study, assessed PSA doubling time over time for geometric or linear progression. The authors reported that those who had geometric progression were treated as opposed to patients with linear progression who were just observed.

The study included 895 men from 2 institutions. The authors stated that average follow up was 10 years. 10.3% of PSA doubling time was linear in this study. PSA doubling time was recalculated with each new PSA value using a best-fit line, and only PSA doubling times beyond BCR were graphed.

auaThe authors found that patients who had linear progressions with PSA doubling times had lower Gleason scores but had similar pathological stage, lymph node and seminal vesicle status to patients who had geometric progression in their PSA doubling times. The mean number of PSA values per patient was 13.5 beyond BCR and 18.7 in total. The average newest PSA doubling time was 30.4 as authors reported.

The authors concluded that 10-15% of men with BCR appear to have a recurrence in prostate cancer that is linear and may be observed without immediate treatment. The linear increase in PSA doubling times as seen in this patient cohort may be significant clinically as it can potentially prevent over treatment of prostate cancer in patients because, with a longer doubling time, there will likely not be any advancement in the disease in a short amount of time.

Presented by Thomas Ahlering, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

University of California (Irvine), Orange, CA USA

Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com

 

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe

Calendar
Upcoming educational events
March 28-31, 2019 / Disney's Grand Floridian Resort & Spa
51st Duke Urologic Assembly and Urologic Cancer Symposium
April 1-5, 2019 / Fairmont Château Laurier
11th International Symposium on Targeted-Alpha-Therapy (TAT11)
April 5-6, 2019 / Imperial College London
Prostate Imaging & Focal Therapy Masterclass 2018